Preclinical studies demonstrated that its combination with Programmed Death-Ligand 1 (PD-L1) blockade significantly reduced MDSC infiltration and enhanced CD8+ T cell activity in Hepatocellular Carcinoma (HCC) models (90). Here, CD8A is linked to hepatocellular carcinoma.